Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Oct 15;102(8):1627–1633. doi: 10.1172/JCI3914

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

N E Lane 1, S Sanchez 1, G W Modin 1, H K Genant 1, E Pierini 1, C D Arnaud 1
PMCID: PMC509014  PMID: 9788977

Abstract

Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (+/-SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35+/-5.5% and 11+/-1.4%, respectively, compared with a relatively small change of 1.7+/-1.8% and 0+/-0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid- induced osteoporosis who are taking hormone replacement.

Full Text

The Full Text of this article is available as a PDF (162.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
  2. Adachi J. D., Bensen W. G., Hodsman A. B. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 1993 Jun;22(6):375–384. doi: 10.1016/s0049-0172(05)80029-0. [DOI] [PubMed] [Google Scholar]
  3. Black D. M., Cummings S. R., Karpf D. B., Cauley J. A., Thompson D. E., Nevitt M. C., Bauer D. C., Genant H. K., Haskell W. L., Marcus R. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535–1541. doi: 10.1016/s0140-6736(96)07088-2. [DOI] [PubMed] [Google Scholar]
  4. Black D. M., Palermo L., Nevitt M. C., Genant H. K., Epstein R., San Valentin R., Cummings S. R. Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res. 1995 Jun;10(6):890–902. doi: 10.1002/jbmr.5650100610. [DOI] [PubMed] [Google Scholar]
  5. Brockstedt H., Christiansen P., Mosekilde L., Melsen F. Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery. Bone. 1995 Jan;16(1):109–117. doi: 10.1016/s8756-3282(94)00017-4. [DOI] [PubMed] [Google Scholar]
  6. Cummings S. R., Black D. M., Nevitt M. C., Browner W., Cauley J., Ensrud K., Genant H. K., Palermo L., Scott J., Vogt T. M. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993 Jan 9;341(8837):72–75. doi: 10.1016/0140-6736(93)92555-8. [DOI] [PubMed] [Google Scholar]
  7. Dempster D. W., Arlot M. A., Meunier P. J. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1983 Jul;35(4-5):410–417. doi: 10.1007/BF02405069. [DOI] [PubMed] [Google Scholar]
  8. Guaydier-Souquières G., Kotzki P. O., Sabatier J. P., Basse-Cathalinat B., Loeb G. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int. 1996;6(2):171–177. doi: 10.1007/BF01623943. [DOI] [PubMed] [Google Scholar]
  9. Hall G. M., Daniels M., Doyle D. V., Spector T. D. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 1994 Oct;37(10):1499–1505. doi: 10.1002/art.1780371014. [DOI] [PubMed] [Google Scholar]
  10. Lane N. E., Thompson J. M., Strewler G. J., Kinney J. H. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res. 1995 Oct;10(10):1470–1477. doi: 10.1002/jbmr.5650101007. [DOI] [PubMed] [Google Scholar]
  11. Lee K., Deeds J. D., Chiba S., Un-No M., Bond A. T., Segre G. V. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology. 1994 Jan;134(1):441–450. doi: 10.1210/endo.134.1.8275957. [DOI] [PubMed] [Google Scholar]
  12. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D., Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997 Aug 23;350(9077):550–555. doi: 10.1016/S0140-6736(97)02342-8. [DOI] [PubMed] [Google Scholar]
  13. Lukert B. P., Johnson B. E., Robinson R. G. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 1992 Sep;7(9):1063–1069. doi: 10.1002/jbmr.5650070909. [DOI] [PubMed] [Google Scholar]
  14. Lukert B. P., Raisz L. G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990 Mar 1;112(5):352–364. doi: 10.7326/0003-4819-112-5-352. [DOI] [PubMed] [Google Scholar]
  15. Meng X. W., Liang X. G., Birchman R., Wu D. D., Dempster D. W., Lindsay R., Shen V. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res. 1996 Apr;11(4):421–429. doi: 10.1002/jbmr.5650110402. [DOI] [PubMed] [Google Scholar]
  16. Mosekilde L., Danielsen C. C., Gasser J. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology. 1994 May;134(5):2126–2134. doi: 10.1210/endo.134.5.8156913. [DOI] [PubMed] [Google Scholar]
  17. Neer M., Slovik D. M., Daly M., Potts T., Jr, Nussbaum S. R. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporos Int. 1993;3 (Suppl 1):204–205. doi: 10.1007/BF01621907. [DOI] [PubMed] [Google Scholar]
  18. Reeve J., Bradbeer J. N., Arlot M., Davies U. M., Green J. R., Hampton L., Edouard C., Hesp R., Hulme P., Ashby J. P. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int. 1991 Jun;1(3):162–170. doi: 10.1007/BF01625448. [DOI] [PubMed] [Google Scholar]
  19. Riggs B. L., Hodgson S. F., O'Fallon W. M., Chao E. Y., Wahner H. W., Muhs J. M., Cedel S. L., Melton L. J., 3rd Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990 Mar 22;322(12):802–809. doi: 10.1056/NEJM199003223221203. [DOI] [PubMed] [Google Scholar]
  20. Saag K. G., Emkey R., Schnitzer T. J., Brown J. P., Hawkins F., Goemaere S., Thamsborg G., Liberman U. A., Delmas P. D., Malice M. P. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292–299. doi: 10.1056/NEJM199807303390502. [DOI] [PubMed] [Google Scholar]
  21. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993 Jun 17;328(24):1747–1752. doi: 10.1056/NEJM199306173282404. [DOI] [PubMed] [Google Scholar]
  22. Silve C. M., Hradek G. T., Jones A. L., Arnaud C. D. Parathyroid hormone receptor in intact embryonic chicken bone: characterization and cellular localization. J Cell Biol. 1982 Aug;94(2):379–386. doi: 10.1083/jcb.94.2.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Singer F. R., Aldred J. P., Neer R. M., Krane S. M., Potts J. T., Jr, Bloch K. J. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest. 1972 Sep;51(9):2331–2338. doi: 10.1172/JCI107044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Slovik D. M., Rosenthal D. I., Doppelt S. H., Potts J. T., Jr, Daly M. A., Campbell J. A., Neer R. M. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986 Aug;1(4):377–381. doi: 10.1002/jbmr.5650010411. [DOI] [PubMed] [Google Scholar]
  25. Tam C. S., Heersche J. N., Murray T. M., Parsons J. A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982 Feb;110(2):506–512. doi: 10.1210/endo-110-2-506. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES